Analyst consensus rating
Cue Biopharma Analyst Rating: Strong Buy
Direct answer
Cue Biopharma's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $88.00.
Forecast evidence checked October 13, 2026.
Get free Cue Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $19.57
- Average price target
- $88.00
- High price target
- $115.00
- Low price target
- $66.00
- Low target gap
- +237.3%
- Target upside
- +349.7%
- High target gap
- +487.6%
- Target range width
- 250.4%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- October 13, 2026
- Valid through
- October 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cue Biopharma?
Cue Biopharma has a verified Strong Buy consensus. The same dataset has an average price target of $88.00.
How far are Cue Biopharma's low and high targets from the recorded price?
The low target implies +237.3%, while the high target implies +487.6%.
How many analysts are included in Cue Biopharma's consensus?
The verified consensus includes 3 analysts.
How is Cue Biopharma's target upside or downside calculated?
The average target of $88.00 is divided by the recorded price of $19.57, then one is subtracted to produce +349.7%. This does not guarantee a future return.
When was Cue Biopharma's analyst forecast verified?
The data was verified on 2026-10-13. The dataset is valid through 2026-10-20.